Hemophilia is a bleeding disorder that occurs when a clotting factor is deficient or inactive. It is characterized by delayed blood coagulation resulting in prolonged bleeding, oozing and seepage of blood into body tissue or spaces. The severity of hemophilia is dependent upon which clotting factor is effected and the extent of the deficiency. In mild forms, the disease can go undetected until a major injury or surgical procedure reveals a coagulation defect. In severe cases, heavy bleeding occurs after minor trauma or even in the absence of injury (spontaneous bleeding). Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs.

Hemophilia is most often the result of an abnormality in Factor 8 or Factor 9 (intrinsic pathway), therefore the aPTT is prolonged and is used as a screening test for the disease. The patient with hemophilia usually has a normal PT and a normal platelet count.

There are several types of hemophilia

Hemophilia A and hemophilia B can result from spontaneous or inherited X chromosome mutations. Inherited hemophilia A and B are passed in an X-linked recessive pattern. In males, a significant mutation in the one copy of the X-linked gene responsible for transcribing F8 of F9 is sufficient to cause the condition. Females have two copies of the F8 and F9 genes, therefore both copies would have to be deficient to cause the disorder. Because it is unlikely that females will have two deficient copies of this gene, it is very rare for females to have hemophilia.

A characteristic of X-linked inheritance is that fathers do not pass X-linked traits to their sons. In X-linked recessive inheritance, a female with one altered copy of the gene in each cell is called a carrier. Carrier females have about half the usual amount of coagulation F8 or coagulation factor IX, which is generally enough for normal blood clotting. However, about 10 percent of carrier females have less than half the normal amount of one of these coagulation factors; these individuals are at risk for abnormal bleeding, particularly after an injury, surgery, or tooth extraction


Hemophilia A can be cured by a liver transplant, but the risks involved in the surgery and the requirement for lifelong medications to prevent rejection of the new liver usually outweigh the benefits for all those without liver disease. For those who are not liver transplant candidates, anti-hemophilic factor replacement products are the treatment of choice. In general, administration of anti-hemophilic factor is indicated for hemophilia when a bleeding episode arises (demand treatment) or when bleeding is anticipated or likely (prophylactic treatment).

The goal of prophylactic therapy is to intervene early and to maintain F8 or F9 above the 1% level between doses. In cases with repeated episodes of spontaneous bleeding, continuous prophylactic therapy may be needed.

A small number of patients with a normal F8 or F9 genes and about 20% of hemophilia A patients develop inhibitor antibodies to F8 or F9. Currently the management of clotting factor inhibition takes two forms:


RnCeus Homepage | Course catalog | Discount prices | Login | Nursing jobs | Help